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1
P atients with atrial fibrillation (AF) and recent ischemic stroke (IS) are at particularly high risk of recurrent IS and other major vascular events. Current antithrombotic therapy guidelines recommend oral anticoagulation (OAC) alone for the secondary prevention of IS in this high-risk population.
1,2 However, these guidelines are largely based on evidence from randomized-controlled trials that did not include patients with acute IS, [3] [4] [5] [6] [7] [8] a population where the risk-benefit ratio of different antithrombotic regimens may differ from a lower risk population. In particular, clinicians may consider using combination OAC and antiplatelet therapy in patients with coexisting cardiac disease, or patients who had their incident stroke while on therapeutic anticoagulation. In contrast, clinicians may be concerned about the use of OAC in patients with severe stroke, given the potential for erratic anticoagulant control and a perceived increased bleeding risk, or when the focus of care is more palliative. With the exception of the European Atrial Fibrillation Trial (EAFT), all randomized-controlled trials evaluating antithrombotic therapy in patients with AF included primary prevention populations. Moreover, the EAFT trial does not inform the management of patients with severe stroke, as these patients were excluded from this trial, and it did not evaluate the safety and efficacy of combination OAC and antiplatelet therapy. 8 In this study, we describe the pattern of use of antithrombotic therapy in consecutive patients with AF discharged from hospital after acute IS and evaluate the association between antithrombotic regimen on discharge and subsequent risk of major vascular events and major bleeding on extended follow up. We pay particular attention to patients with severe stroke, and those with concomitant coronary heart disease (CHD).
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Methods

Population
The Registry of the Canadian Stroke Network is a prospective registry of consecutive patients with acute stroke or transient ischemic attack presenting to the emergency department or admitted to hospital in 12 regional stroke centers in Ontario, Canada. The Registry of the Canadian Stroke Network is a prescribed registry under the Ontario Personal Health Information Protection Act, allowing data collection without individual patient consent and ensuring the inclusion of consecutive patients. The Registry of the Canadian Stroke Network was approved by the Research Ethics Board of Sunnybrook Health Sciences Center. We included consecutive patients with acute IS and AF admitted to hospital between July 1, 2003, and March 31, 2008 . For the purposes of our study, AF was defined as previous history of AF, AF diagnosed in the emergency room, or new-onset AF detected during hospitalization. Our analysis was confined to patients alive at hospital discharge.
Outcome Measures
The primary outcome was the composite of death or hospital readmission for recurrent IS, myocardial infarction (MI), or major bleeding. Secondary outcomes included hospital admission for recurrent IS, MI, major bleeding, intracerebral hemorrhage (ICH), all-cause mortality, and combinations of these outcomes (Internation Classification of Diseases, 10th revision codes in Appendix I in the online-only Data Supplement).
Covariates
We included baseline variables previously reported to be associated with poor outcomes after IS. Variables were divided into (1) preadmission variables, including congestive heart failure, hypertension, age >75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease (previous myocardial infarction, peripheral arterial disease or aortic plaque), age 65-74 years, sex category (female) (CHA 2 DS 2 VASc) Score, preadmission dependence, peptic ulcer disease, valvular heart disease/valve replacement, deep venous thrombosis or pulmonary embolism, cirrhosis, gastrointestinal or intracranial bleed, anemia on admission, thrombocytopenia on admission, and renal impairment and (2) discharge variables, including modified Rankin score (0-1, 2-3, and 4-5), antithrombotic therapy on discharge (no antithrombotic therapy, antiplatelet therapy alone, OAC [warfarin] alone or combination OAC plus antiplatelet therapy) and use of statins, antihypertensives, or proton pump inhibitors on discharge (see Appendix II for variable definitions in the online-only Data Supplement).
Statistical Analysis
For descriptive analyses, χ 2 tests were used to compare categorical variables and one-way ANOVA for continuous variables. We calculated adjusted proportions for each outcome, adjusting for the variables listed above. Multivariable Cox proportional hazard models were generated to determine the association between antithrombotic regimen on discharge and time to death or admission for major vascular events or bleeding after acute IS, adjusting for the covariates listed above.
Our primary analysis included the entire cohort, but we also completed subgroup analyses in (1) patients with CHD; and (2) patients at low risk of major bleeding (see Appendix II for definitions in the online-only Data Supplement). For all analyses, a 95% confidence interval (CI) that did not include 1.0, or P<0.05, were considered to be statistically significant. All analyses were conducted using SAS statistical software, version 9.2 (SAS Institute Inc, Cary, NC).
Results
During the study period (July 1, 2003 to March 31, 2008), 2162 patients with AF were discharged alive following acute IS, of whom 8.0% (172) were prescribed no antithrombotic therapy on discharge, 21.6% (468) were prescribed antiplatelet therapy alone, 39.3% (850) were prescribed OAC alone, and 31.1% (672) were prescribed combination OAC and antiplatelet therapy ( Figure I in the online-only Data Supplement). Patients at high risk of bleeding (eg, prior intracranial hemorrhage, prior gastrointestinal hemorrhage, history of peptic ulcer disease, thrombocytopenia on admission, and hemorrhagic stroke during hospitalization) were less likely to be prescribed OAC on discharge, either alone or in combination with antiplatelet therapy. Patients discharged on combination OAC and antiplatelet therapy had a higher cardiovascular risk profile (including a higher prevalence of comorbidities and in hospital medical complications, such as recurrent IS and MI), as well as a higher frequency of severe strokes, compared with patients discharged on OAC alone ( 
Mortality
On multivariable analysis, compared with OAC alone on discharge, no antithrombotic therapy (HR, 1.57; 95% CI, 1.26-1.95) and antiplatelet therapy alone (HR, 1.42; 95% CI, 1.23-1.64) were associated with an increased risk of death over 4 years, whereas combination OAC and antiplatelet therapy was associated with a similar risk of death (HR, 0.94; 95% CI, 0.82-1.08; Table II in the online-only Data Supplement).
Admission for Major Bleeding and ICH
During follow-up, 8.6% (185) of patients were admitted for major bleeding. On multivariable analysis, compared with OAC alone on discharge, no antithrombotic therapy (HR, 0.51; 95% CI, 0.23-1.15) and antiplatelet therapy alone (HR, 0.79; 95% CI, 0.51-1.22) were associated with a trend toward a reduced risk of admission for major bleeding, whereas combination OAC and antiplatelet therapy was associated with a trend toward an increased risk of admission for major bleeding (HR, 1.30; 95% CI, 0.94-1.80). Addition of antiplatelet to OAC therapy was not associated with an increased risk of admission for ICH >4 years over the 4-year follow-up period (HR, 1.05, 95% CI, 0.53-2.11; Table II in the online-only Data Supplement). In a sensitivity analysis of patients with a low risk of bleeding, results were not materially altered (Table III in the online-only Data Supplement). A test for an interaction between bleeding risk (high versus low) and combination OAC and antiplatelet therapy on discharge was not significant, P=0.79.
Subgroup Analyses
Patients With Severe Stroke (Modified Rankin Score 4-5 on Discharge) In the cohort, 41.9% (903) of patients experienced a severe stroke, defined as a modified Rankin score of 4 to 5 on discharge. On multivariable analysis, compared with OAC alone on discharge, no antithrombotic therapy (HR, 1.58; 95% CI, 1.21-2.06) and antiplatelet therapy alone (HR, 1.34; 95% CI, 1.09-1.63) were associated with an increased risk of the composite of death or admission for recurrent IS, MI, or major bleeding (Table III in the online-only Data Supplement). A test for an interaction between baseline stroke severity (moderate versus severe) and combination OAC and antiplatelet therapy on discharge was not significant, P=0.4. A test for an interaction between baseline stroke severity (mild versus severe) and combination OAC and antiplatelet therapy on discharge was also not significant, P=0.91. 
Patients With CHD
Stroke
increased risk of the composite of death or admission for recurrent IS, MI, or major bleeding over the 4-year followup period, whereas combination OAC and antiplatelet therapy was associated with a trend toward a reduced risk of the composite (HR, 0.79; 95% CI, 0.61-1.02; a test for an interaction between history of CHD and combination OAC and antiplatelet therapy on discharge was not significant, P=0.26). Secondary outcomes are reported in Table III in the onlineonly Data Supplement.
Discussion
Following recent IS in patients with AF, one third of patients are not managed according to current antithrombotic guideline recommendations (ie, OAC alone). The use of OAC is associated with improved stroke outcomes, even in patients with severe stroke. Addition of antiplatelet therapy to OAC may reduce the risk of recurrent stroke and MI in high-risk patients although at the expense of an increased risk of major bleeding. Nonadherence with current guideline recommendations for OAC alone in patients with IS and AF may occur for several reasons. First, clinicians may believe that their individual patients are not represented in the evidence-base that supports current guidelines recommendations, because they present a higher risk of thromboembolism or a lower risk of major bleeding, than the average patient included in clinical trials. The only randomized-controlled trial to evaluate OAC (ie, warfarin) after acute IS was the EAFT, which excluded patients with severe stroke and those with recent CHD, and targeted a higher international normalized ratio intensity (international normalized ratio, 2.5-4.0) than that currently recommended. Some patients not represented in EAFT may be considered to have a higher cardiovascular risk (eg, those with prior CHD), thus clinicians may choose to add antiplatelet therapy to OAC. In our study, patients prescribed combination therapy had a higher risk factor profile than those prescribed OAC alone, supporting this contention. Overall, 30% of patients were discharged on combination OAC and antiplatelet therapy, a similar rate to that reported in a smaller study (34.7%; n=291). 9 A meta-analysis of clinical trials of primary prevention populations with AF did not report a reduction in major vascular events with OAC and antiplatelet therapy, compared with OAC alone, but did report an increased risk of major bleeding. 10 However, the populations included in those trials were at lower cardiovascular risk than patients with recent IS and prior CHD. In our cohort, the absolute rate of recurrent IS or MI was 13.7% at 4 years. We found an increased risk of major bleeding (6.5% versus 8.3%), but not ICH (1.8% versus 1.8% at 4 years), with the addition of antiplatelet therapy to OAC, and a lower risk of recurrent IS or MI (14.1% versus 11.8%), despite a higher baseline vascular risk profile in the combination therapy group (Table 2) . Previous studies have reported conflicting findings on the risk of major bleeding, including ICH, in patients with AF treated with combination therapy compared with OAC alone. [11] [12] [13] [14] [15] [16] [17] In our study, the net clinical effect seemed to favor combination therapy; however, the observational nature of our study means that our results should not form the basis for clinical recommendations, rather they seem to support the need for clinical trials comparing combination therapy to OAC alone in this population. Furthermore, given the increasing uptake of newer anticoagulant agents in patients with AF, and the reduced risk of anticoagulant-related ICH with these agents compared with warfarin, potentially lowering the threshold for adding antiplatelet therapy, such trials will be essential for informing evidence-based clinical decision making in this population. Second, in other patients, clinicians may be particularly concerned about the risks of major bleeding, and uncertain about whether the benefits of OAC outweigh the risks. For example, in patients with severe stroke, withholding of any antithrombotic therapy may be part of an overall palliative approach to care. In our study, patients not prescribed any antithrombotic therapy had lower rates of statin and antihypertensive therapy use, and the observed reduction in readmission rates in patients discharged on no antithrombotic therapy compared with antiplatelet therapy, may mainly reflect a change in management emphasis. In contrast, patients prescribed antiplatelet therapy alone had similar rates of statin and antihypertensive therapy use to those prescribed OAC, suggesting a similar overall focus on active management of secondary prevention in patients discharged on antiplatelet compared with OAC therapy. In many of these patients, the decision to not prescribe OAC is likely based on the perceived risk of bleeding, rather than the actual risk, considering the low rates of prior (4.3%), and in-hospital bleeding (2.8%), we observed in our cohort (Table 1; Table I in the online-only Data Supplement). An especially challenging group are those with severe stroke (modified Rankin Score, 4-5), where we have no clinical trials to guide recommendations, and limited observational data on the actual risk of major bleeding. The absolute rate of admission for major bleeding during the first year was 2.0% in those prescribed OAC (Table V in the online-only Data Supplement), one third of whom had severe stroke, which is similar to the rate of major bleeding reported in EAFT (2.8% per year), suggesting that the perceived risk of major bleeding may be exaggerated. In addition, among those with severe stroke, we found that prescribing of OAC was associated with a reduction in major vascular events compared with antiplatelet therapy alone. Much of this association was related to a reduction in mortality, which has not been reported in prior trials comparing OAC with aspirin. 1, 18 Collectively, these observations prompt the need for further research on the efficacy and safety of OAC therapy in patients with severe stroke, where there is currently much clinical uncertainty, as evidenced by the large variation in prescribing patterns.
Finally, nonadherence may be due to oversight of the need for OAC, or unintentional failure to stop antiplatelet therapy once OAC is introduced, rather than a conscious decision. In our study, the high rates of prescribing of other secondary preventative therapies (statins, antihypertensives) in those receiving antithrombotic therapy would argue against oversight being a major contributor, and the higher risk profile of those prescribed combination antithrombotic therapy suggests active decision making. However, we were unable to exclude completely the effects of clinician behavior and other unmeasured confounders in our analyses.
Other limitations of our study are (1) the inclusion of patients presenting to specialized stroke centers, and so results may not be applicable to all patients with IS. However, the prevalence of AF in our study (26.2%) is broadly in line with figures reported in previous studies (15% to 25%), 19 supporting the generalizability of our results; (2) our cohort included patients with acute IS and AF admitted to stroke centers between 2003 and 2008, and changes in practice patterns in Adjusted rates reflect adjustment for congestive heart failure, hypertension, age >75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease (previous myocardial infarction, peripheral arterial disease or aortic plaque), age 65-74 years, sex category (female) (CHA 2 DS 2 VASc) Score, preadmission dependence, history of peptic ulcer disease, valvular heart disease or valve replacement, deep venous thrombosis or pulmonary embolism, cirrhosis, prior gastrointestinal bleed, prior intracranial bleed, hemoglobin <11.5 g/dL in females or <13 g/dL in males on admission, platelets <100×10
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December 2014 more recent years, such as greater uptake of secondary preventative therapies, may also influence outcome rates. However, the proportion of patients prescribed OAC in our study (70%) is similar to that in more recent registries (72.1%), 20 supporting the external validity of our findings; (3) we did not have access to data on introduction of, or changes to, antithrombotic therapy after hospital discharge, as well as data on adherence or international normalized ratio control in those discharged on OAC therapy. More than 50% of patients have been reported to discontinue warfarin during the first 2 years after acute IS. 21 However, our study was designed to evaluate the association between antithrombotic prescribing at the time of discharge and subsequent risk of major vascular events. The strengths of our study include the large sample size; inclusion of consecutive patients from a large prospective registry, minimizing the potential for selection bias; and completeness of data at baseline, discharge, and follow up.
Conclusions
Over 60% of patients with AF discharged after acute IS are not managed according to current antithrombotic guideline recommendations. We suspect that this primarily reflects a disconnect between patients included in clinical trials, on which current guidelines are based, and those encountered in real-life clinical practice. Clinical trials are required to determine the efficacy, tolerability, and safety of OAC in those with severe stroke, and the addition of antiplatelet therapy to OAC in those at high cardiovascular risk, particularly the addition of antiplatelet therapy to newer oral anticoagulant agents, given the more favorable risk-benefit ratio of the newer agents compared with warfarin. Appendix II: Definitions of variables  Coronary heart disease was defined as prior myocardial infarction, prior percutaneous coronary intervention or prior coronary artery bypass grafting  CHA2DS2VASc score was defined as: history of congestive heart failure, history of hypertension, age (by decade), diabetes mellitus (including a history of diabetes mellitus or glucose 7.5mmol/L on admission), prior stroke, vascular disease including coronary heart disease [coronary heart disease was defined as prior myocardial infarction, prior percutaneous coronary intervention or prior coronary artery bypass grafting] and peripheral vascular disease, and sex (female)  Preadmission dependence was defined as dependency in activities of daily living in the three months prior to admission  Anemia was defined as a hemoglobin on admission <11.5g/dL in females or <13g/dL in males  Renal impairment was defined as renal dialysis or creatinine on admission >120 mol/L in males or >110 mol/L in females  Patients with a low risk of major bleeding were defined as those who met each of the following criteria: a) prescribed antithrombotic therapy on discharge, b) mRankin score 0-3 on discharge, c) platelets >100 x 10 9 /L on admission, d) Hgb >11.5 g/dL F, >13 g/dL M on admission, e) preadmission independence, f) no prior hemorrhagic stroke or GI bleed, g) no known cirrhosis, h) no preadmission dementia, i) no bleeding during hospitalization for acute ischemic stroke and j) no known PUD; and 3) Patients with severe stroke (mRankin score 4-5 on discharge). 
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